<p>China Medical System Holdings Limited announced that its self-developed innovative drug, CMS-D017, a novel selective small-molecule inhibitor of complement factor B, has received Drug Clinical Trial Approval from the National Medical Products Administration (NMPA) of China. The approval allows the company to conduct clinical trials in healthy participants in China to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of CMS-D017, which is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The company is actively preparing to initiate the relevant clinical trials. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12006476), on January 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>China Medical System Holdings Limited has received approval from the National Medical Products Administration (NMPA) to begin clinical trials for its innovative drug CMS-D017, a selective small-molecule inhibitor of complement factor B. The trials will assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants, targeting the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The company is preparing to initiate these trials.</p>

Reuters

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

China Medical System Holdings Receives NMPA Approval to Begin Clinical Trials for CMS-D017